Skip to content

EBIT at other companies

Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
-$8.33M+18.8%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$112.33M-54.4%
Biohaven logo
BiohavenBHVN
-$130.43M+41.1%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$13.3M+48.7%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.91B+309%

Returns & leverage

See full
Return on equity-28.3%
Debt / equity0.0×
Current ratio27.1×-3.9×

Where this comes from

Calculated from Rapport Therapeutics, Inc.’s reported figures.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s EBIT?
Rapport Therapeutics, Inc. (RAPP) reported EBIT of -$24.22M in Q1 2026.
How has Rapport Therapeutics, Inc.'s EBIT changed year-over-year?
Rapport Therapeutics, Inc.'s EBIT increased by 10.7% year-over-year, from -$27.11M to -$24.22M.
What is the long-term trend for Rapport Therapeutics, Inc.'s EBIT?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s EBIT has grown at a 86.0% compound annual growth rate (CAGR), from -$36.18M to -$125.1M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.